94% of researchers rate our articles as excellent or good
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.
Find out more
CASE REPORT article
Front. Med.
Sec. Infectious Diseases: Pathogenesis and Therapy
Volume 12 - 2025 | doi: 10.3389/fmed.2025.1541235
This article is part of the Research Topic Infectious Diseases and Hematology: Diagnosis and Management - Volume II View all 7 articles
Dose determination of VV116 in COVID-19 patients with severe liver dysfunction: a case report
Provisionally accepted
Jing Yang 1
Wenwen Jiang 2* Jianqing Deng 3* Min Liu 3* Ya Xue 1* Jizhang Bao 3* Tingting Jia 1* Qi Hu 3* Lichao Zhang 1*- 1 Department of Pharmacy, Shanghai Municipal Hospital of Traditional Chinese Medicine, Shanghai, China
- 2 Department of Hematology, Shanghai University of Traditional Chinese Medicine, Shanghai, China
- 3 Department of Hematology, Shanghai Municipal Hospital of Traditional Chinese Medicine, Shanghai, China
VV116 is an oral antiviral drug against SARS-CoV-2, known for its favorable efficacy and safety profile. But its application in patients with severe liver dysfunction has not been evaluated. Here, we report a case in which a patient with aplastic anemia and liver impairment (recovery phase of acute liver failure) was infected SARS-CoV-2. Based on clinical trials and pharmacokinetic analysis about VV116, we initiated a reduced dose of 300 mg every 12 hours on day 1, 200 mg every 12 hours on days 2-5 for antiviral therapy. Finally, the patient's viral load rapidly dropped to an undetected level, and no drug-related adverse effects were observed.
Keywords: COVID-19, VV116, Liver dysfunction, Dosage adjustment, SARS-CoV-2
Received: 07 Dec 2024; Accepted: 07 Feb 2025.
Copyright: © 2025 Yang, Jiang, Deng, Liu, Xue, Bao, Jia, Hu and Zhang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Wenwen Jiang, Department of Hematology, Shanghai University of Traditional Chinese Medicine, Shanghai, China
Jianqing Deng, Department of Hematology, Shanghai Municipal Hospital of Traditional Chinese Medicine, Shanghai, 200071, China
Min Liu, Department of Hematology, Shanghai Municipal Hospital of Traditional Chinese Medicine, Shanghai, 200071, China
Ya Xue, Department of Pharmacy, Shanghai Municipal Hospital of Traditional Chinese Medicine, Shanghai, 200071, China
Jizhang Bao, Department of Hematology, Shanghai Municipal Hospital of Traditional Chinese Medicine, Shanghai, 200071, China
Tingting Jia, Department of Pharmacy, Shanghai Municipal Hospital of Traditional Chinese Medicine, Shanghai, 200071, China
Qi Hu, Department of Hematology, Shanghai Municipal Hospital of Traditional Chinese Medicine, Shanghai, 200071, China
Lichao Zhang, Department of Pharmacy, Shanghai Municipal Hospital of Traditional Chinese Medicine, Shanghai, 200071, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.